Please select the eligibility criteria that correspond to the clinical trial below.
Title: Interventions for Chronic Diseases: Effect of Patient Values and Effectiveness Information on Patients' Choice of Therapy, Adherence to Therapy and Satisfaction With Therapy
Brief Summary: Few studies have explored how specific formats of effectiveness information effect on real patients' decisions. We only know little about what kind of format would be the optimal to help patients make well-informed real-life decisions corresponding to their preferences.

The trial is developed in a clinical randomised design to study risk communication in the shared decision making between general practitioners (GP) and their patients in primary prevention with of cholesterol lowering drug. Endpoints are effect of GPs' information about treatment effectiveness and their patients' values on patients' tendency to accept and adhere to the treatment as well as their feeling of content with the choice made. GPs are randomised to inform about risk and treatment effectiveness by means of either absolute risk reduction (ARR) or Prolongation of Life (POL). Afterwards patients are invited to answer questionnaires concerning their content with decisions and reflections. Patients' redemption of prescriptions during the following week and the first year are recorded through an electronic database.

57 GPs and 248 patients have been enrolled in the trial.


Options:
A: Patient or family member meeting 1 of the following revised Bethesda colorectal cancer (CRC) criteria:

* Diagnosis of colon or rectal cancer at \< 50 years of age
* Diagnosis of \> 1 CRC at one time in the past
* Diagnosis of ≥ 1 CRC at different times
* Diagnosis of CRC and any other hereditary nonpolyposis colorectal cancer (HNPCC)-related cancers
* Diagnosis of CRC in ≥ 2 first-degree or second-degree relatives with HNPCC-related tumor and ≥ 1 cancer diagnosed at \< 50 years of age
* Diagnosis of CRC in ≥ 2 first- or second-degree relatives with HNPCC-related tumors, regardless of age
* Diagnosis of CRC with pathologic features suggestive of microsatellite instability (MSI) and \< 60 years of age

  * Patients with CRC meeting the Amsterdam criteria defined below are ineligible:
* Three relatives with CRC with 1 being a first-degree relative of the other 2
* Cases that span ≥ 2 generations
* At least 1 CRC case diagnosed before 50 years of age

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* Not specified
B: Inclusion Criteria:

* 40-69 year-olds
* Patients with a measured total-cholesterol of \> 4 MMol/Litre

Exclusion Criteria:

* Patients with diabetes
* Patients with known chronic cardiovascular diseases
* Patients who are already being treated with cholesterol lowering therapy
* Patients who are not familiar with the danish language
C: Inclusion Criteria:

* type 2 diabetes
* stated concern about diabetes and diabetes treatment
* poor glycemic control
* over 21 years of age

Exclusion Criteria:

* blind, deaf, otherwise unable to use the telephone or visual resources
* pregnant
* currently enrolled in other REACH Detroit research study
* in hospice care
* current radiation or chemotherapy
D: DISEASE CHARACTERISTICS:

* Must have at least 10% chance of carrying the BRCA1/BRCA2 gene, as defined by ≥ 1 of the following:

  * First-degree relative of affected family member with a 50% chance of inheriting a BRCA1/BRCA2 mutation
  * Second-degree relative with BRCA1/BRCA2 mutation with 25% risk of inheritance (parent deceased)
  * Obligate gene carrier or affected woman
* Must live within 100 miles of the Lombardi Comprehensive Cancer Center
* No more than 4 weeks since breast or ovarian cancer diagnosis
* No metastatic or inflammatory breast cancer or ovarian cancer
* No stage III breast or ovarian cancer while undergoing concurrent chemotherapy

PATIENT CHARACTERISTICS:

* No psychiatric illness or cognitive disorder that would preclude informed consent

PRIOR CONCURRENT THERAPY:

* No prior genetic counseling or testing for BRCA1 and/or BRCA2

Answer: B